Immunotherapy with agonistic anti-CD137

two sides of a coin.

Yonglian Sun, Jonathan H. Chen, Yangxin Fu

Research output: Contribution to journalReview article

26 Citations (Scopus)

Abstract

CD137 (4-1BB), a member of the TNF receptor superfamily, is an inducible T cell costimulatory receptor primarily expressed on activated CD4+ and CD8+ T cells. Agonistic monoclonal antibodies (mAbs) against CD137 greatly enhance T cell-mediated immune responses against many types of tumors and viruses. Surprisingly, these agonists also showed therapeutic effects in several autoimmune diseases. These findings suggest that in different disease environments, CD137 engagement with agonist mAb in vivo can diametrically modulate immune response outcomes. Therefore, CD137 agonists represent a promising immunotherapeutic approach to a wide array of disparate immune disorders. However, CD137's potency in modulating immune response necessitates caution when targeting CD137 clinically.

Original languageEnglish (US)
Pages (from-to)31-36
Number of pages6
JournalCellular & molecular immunology
Volume1
Issue number1
StatePublished - Jan 1 2004

Fingerprint

Numismatics
Immunotherapy
Costimulatory and Inhibitory T-Cell Receptors
T-Lymphocytes
Oncogenic Viruses
Tumor Necrosis Factor Receptors
Immune System Diseases
Therapeutic Uses
Autoimmune Diseases
Monoclonal Antibodies

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

Immunotherapy with agonistic anti-CD137 : two sides of a coin. / Sun, Yonglian; Chen, Jonathan H.; Fu, Yangxin.

In: Cellular & molecular immunology, Vol. 1, No. 1, 01.01.2004, p. 31-36.

Research output: Contribution to journalReview article

Sun, Yonglian ; Chen, Jonathan H. ; Fu, Yangxin. / Immunotherapy with agonistic anti-CD137 : two sides of a coin. In: Cellular & molecular immunology. 2004 ; Vol. 1, No. 1. pp. 31-36.
@article{9485635ba66f42868f98147c5f9a1e3a,
title = "Immunotherapy with agonistic anti-CD137: two sides of a coin.",
abstract = "CD137 (4-1BB), a member of the TNF receptor superfamily, is an inducible T cell costimulatory receptor primarily expressed on activated CD4+ and CD8+ T cells. Agonistic monoclonal antibodies (mAbs) against CD137 greatly enhance T cell-mediated immune responses against many types of tumors and viruses. Surprisingly, these agonists also showed therapeutic effects in several autoimmune diseases. These findings suggest that in different disease environments, CD137 engagement with agonist mAb in vivo can diametrically modulate immune response outcomes. Therefore, CD137 agonists represent a promising immunotherapeutic approach to a wide array of disparate immune disorders. However, CD137's potency in modulating immune response necessitates caution when targeting CD137 clinically.",
author = "Yonglian Sun and Chen, {Jonathan H.} and Yangxin Fu",
year = "2004",
month = "1",
day = "1",
language = "English (US)",
volume = "1",
pages = "31--36",
journal = "Cellular and Molecular Immunology",
issn = "1672-7681",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Immunotherapy with agonistic anti-CD137

T2 - two sides of a coin.

AU - Sun, Yonglian

AU - Chen, Jonathan H.

AU - Fu, Yangxin

PY - 2004/1/1

Y1 - 2004/1/1

N2 - CD137 (4-1BB), a member of the TNF receptor superfamily, is an inducible T cell costimulatory receptor primarily expressed on activated CD4+ and CD8+ T cells. Agonistic monoclonal antibodies (mAbs) against CD137 greatly enhance T cell-mediated immune responses against many types of tumors and viruses. Surprisingly, these agonists also showed therapeutic effects in several autoimmune diseases. These findings suggest that in different disease environments, CD137 engagement with agonist mAb in vivo can diametrically modulate immune response outcomes. Therefore, CD137 agonists represent a promising immunotherapeutic approach to a wide array of disparate immune disorders. However, CD137's potency in modulating immune response necessitates caution when targeting CD137 clinically.

AB - CD137 (4-1BB), a member of the TNF receptor superfamily, is an inducible T cell costimulatory receptor primarily expressed on activated CD4+ and CD8+ T cells. Agonistic monoclonal antibodies (mAbs) against CD137 greatly enhance T cell-mediated immune responses against many types of tumors and viruses. Surprisingly, these agonists also showed therapeutic effects in several autoimmune diseases. These findings suggest that in different disease environments, CD137 engagement with agonist mAb in vivo can diametrically modulate immune response outcomes. Therefore, CD137 agonists represent a promising immunotherapeutic approach to a wide array of disparate immune disorders. However, CD137's potency in modulating immune response necessitates caution when targeting CD137 clinically.

UR - http://www.scopus.com/inward/record.url?scp=33644823867&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644823867&partnerID=8YFLogxK

M3 - Review article

VL - 1

SP - 31

EP - 36

JO - Cellular and Molecular Immunology

JF - Cellular and Molecular Immunology

SN - 1672-7681

IS - 1

ER -